Once SEBIVO is approved for China, how will NVS/IDIX make a fair profit on selling this drug into a region where that average wage is $55-$85/month for the average worker? Will the Chinese Government pick up the bill for this drug, or will the common Chinese worker be expected to pay for the drug?
Perhaps I should have researched this aspect before I became a IDIX shareholder.
Market Data 
Markets 
AI
